BioPortUSA has been selected by BacTrace to help them launch their rapid Covid-19 antibody test, Racordiax in the USA. Manufactured in Germany, the CE-marked test provides a test result with 99.41% sensitivity and 99.13% specificity in just 10 minutes, using the appropriate smartphone iOS or Android RACORDIAX App. “This has the potential to open up everything and get the economy going again” said Mark Lesselroth, CEO of BioPortUSA.
Today this test which does not require a lab, is targeting point of care providers to administer the test, however, it does have the capability to be used as a take home test down the road. Marc Mileau, CMO for Bactrace noted that “with BioPort’s assistance we hope to find the right strategic sales partner to help bring a solution to the USA which will help curb the fight against Covid-19.” If all goes well, the test should be available for use in the USA by the second quarter of this year.
BacTrace develops portable integrated systems that allow to obtain test results within minutes on site, rather than from a laboratory within days or even weeks. The small size, highly sensitive and validated systems perfectly serve the needs in clinical point-of-care settings to help making fast triage and treatment decisions, as well as in environmental applications, such as water contamination assessment.
The RACORDIAX COVID-19 Antibody Rapid Test uses a blood sample that is simply collected with a lancet and a pipette from the fingertip. This allows the test to be taken at any location quickly, efficiently and safely. To perform the test, one drop of blood and three drops of running buffer are added to a test cassette. After 10 minutes the test cassette is scanned with the smartphone RACORDIAX App. The app, which can be adapted to different data protection regulations, compares the scan within seconds with a database that is secured on a cloud server in Switzerland. Through the support of an artificial intelligence assisted algorithm, a comprehensive diagnosis is then provided.